Latest from UCLA Jonsson Comprehensive Cancer Center

Sara A. Hurvitz, MD, director of the Breast Oncology Program at the University of California, Los Angeles, Jonsson Comprehensive Cancer Center, advises how to navigate therapy for patients with HER2-positive breast cancer.
 
Richard S. Finn, MD, assistant professor of medicine, Department of Medicine, Division of Hematology/Oncology, Geffen School of Medicine, University of California, Los Angeles, discusses sequencing therapy for patients with hepatocellular carcinoma.
Sara A. Hurvitz, MD, director of the Breast Oncology Program, medical director of the Clinical Research Unit, University of California, Los Angeles Jonsson Comprehensive Cancer Center, discusses the impact of biosimilars in the treatment of patients with breast cancer.
Jianyu Rao, MD, discusses the evolution of pathology in gynecologic cancers.
Sara A. Hurvitz, MD, discussed targeted therapy advancements, the rise of trastuzumab biosimilars, and the future of HER2-positive breast cancer treatment.
Sanaz Memarzadeh, MD, PhD, details the early developments of antibody-directed therapies and restoring p53 function in the treatment of patients with ovarian cancer.
John A. Glaspy, MD, discusses challenges and progress with immunotherapy in gynecologic cancers.
Dennis J. Slamon, MD, PhD, discusses new opportunities for treatment advances in ovarian cancer.
Publication Bottom Border
Border Publication
x